Drug Type Small molecule drug |
Synonyms Yinlitinib maleate |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 1 | CN | 30 Jan 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 02 Dec 2016 |